�The link between cholesterol-lowering drug ezetimibe (marketed as Vytorin) and cancer is still not clear, wrote the editors of the leading medical
journal New England Journal of Medicine (NEJM). More time is needed to assess the drug, they said, and in the meantime patients and
doctors will suffer to live with the uncertainty.
The editorial appears in the online first second September topic of NEJM, along with a report of the SEAS clinical trial of lipid-lowering therapy
which tested the combination of zocor and ezetimibe compared with placebo on the incidence of cardiovascular events in older the great unwashed with
aortic valve stenosis (abnormal narrowing of the gist valve that lets ancestry into the aorta).
While the trial establish that the treatment did not halt aortic stricture or demo impact on cardiovascular events in general (apart from one or two
exceptions), it showed an unexpected result in adverse events, where in that respect appeared to be a rise in cancer relative incidence and cancer deaths in the
discussion group compared to the placebo group.
This would make sense, since the way ezetimibe kit and caboodle is to reduce the absorption of cholesterol in the gut, which could also step in with the
absorption of other substances that affect cancer growth.
However, the SEAS researchers suggested that the higher incidence of malignant neoplastic disease in the treatment group could be due to chance, merely agreed further studies
should look into it. A group of epidemiologists from Oxford University did look into it by using the SEAS data and supplementing it with information from deuce
other on-going studies on ezetimibe, SHARP and IMPROVE-IT, which although had shorter follow ups than the four years in the SEAS trial, were
much larger and gave more cancer data. They then examined the three sets of data to see if the imbalance in incident cancers and cancer deaths
from the SEAS trial was replicated in the other two trials.
The Oxford group's analysis failed to confirm the step-up in incident cancer constitute in the SEAS test, but it did confirm the nonsignificant increase in
cancer deaths. Their sketch is also reported in the 2nd September issue of NEJM.
The editors pointed prohibited that it was crucial to note that piece cancer mortality is an end point that one would look to be reliable, none of the trials
was designed to assess this as a primary final result.
When the Oxford grouping combined the data on cancer deaths from the three trials (SEAS, SHARP, and IMPROVE-IT), they found an step-up in jeopardy
of cancer the Crab death in the combined ezetimibe groups (134 versus 92 deaths in controls, showing a risk ratio of 1.45 and an uncorrected P=0.007).
But the Oxford group aforesaid it believed this finding was strictly due to chance and could non be a real climb in cancer death risk because if that were the
example then there should have been a corresponding go up in malignant neoplastic disease incidence.
Again, the editors cautioned that because the test of statistical significance, P, comes from an analysis that combines information from studies with different
objectives, it should be interpreted carefully. They wrote that although the Oxford researchers may ultimately be proved right, patients and doctors
should be cautious because it is not clear whether the increased risk of death is due to chance or not. Because of the way it affects assimilation of
chemicals in the gut, ezetimibe may well affect the balance of cancer fixing substances too.
"The fact that the combined data from all ternion trials showed an increment in crab mortality with ezetimibe should not be assumed to be a chance
finding until further data are in," wrote the editors.
The editors aforementioned the SHARP and IMPROVE-IT trials must go on and there should be careful espouse up of the patients. These and other trials yielding
information on ezetimibe treatments should be analyzed for cancer-related results, they wrote, and mentioned that the US Food and Drug Administration
(FDA) had plans to carry out its own analysis.
"Ezetimibe and Cancer -- An Uncertain Association."
Drazen, Jeffrey M., D'Agostino, Ralph B., Ware, James H., Morrissey, Stephen, Curfman, Gregory D.
N Engl J Med 2008 0: NEJMe0807200; published online low 2 September 2008.
Click here for the full Editorial.
Sources: NEJM.
Written by: Catharine Paddock, PhD
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
More information
Tuesday, 9 September 2008
Thursday, 21 August 2008
Duffy Fears Old Friends Will Think She's Become A Diva
Duffy says she's scared about reverting to her home town of Nefyn in Wales in case people cogitate she has changed.
The isaac Bashevis Singer, who has enjoyed a whirlwind 2008 in both the UK and America, believes the town will be selfsame different when she returns.
�In my mind it hasn�t changed a bit � everyone is still drunkenness in the same bar, dancing in the same club, citizenry are placid in the same darts team,� she told the Daily Star.
�We have a man who whole caboodle in the local chippie called Dick Fish because in Wales they call you by what you do � so I�m Duffy Cantores, which substance singer.
�But I�m freaking kayoed that when I go back the great unwashed will think I�ve changed. Everyone has been so supportive I don�t want them to feel let down.�
Duffy pulled one of the biggest crowds when she performed at the V Festival in Staffordshire and Chelmsford last weekend.
You can see full photograph highlights from both legs of the V Festival below:
V Festival 2008 � Day One, Staffordshire � CLICK HERE
V Festival 2008 � Day One, Chelmsford � CLICK HERE
V Festival 2008 � Day Two, Staffordshire � CLICK HERE
V Festival 2008 � Day Two, Chelmsford � CLICK HERE
You rear see highlights from Duffy's set in Staffordshire below.
Duffy � V Festival 2008, Staffordshire
More info
Monday, 11 August 2008
Wednesday, 2 July 2008
Michael Sandler and Musir Von Vidalia
Artist: Michael Sandler and Musir Von Vidalia
Genre(s):
Ambient
Discography:
Meetingplace
Year: 2005
Tracks: 6
Matthew Rhys - Rhys Disastrous Dates
Tuesday, 24 June 2008
Crimson Glory
Artist: Crimson Glory
Genre(s):
Rock
Metal: Progressive
Metal: Heavy
Discography:
Astronomica CD2 - Live
Year: 1999
Tracks: 3
Astronomica CD1
Year: 1999
Tracks: 10
Astronomica
Year: 1999
Tracks: 10
Strange and Beautiful
Year: 1991
Tracks: 11
Transcendence
Year: 1988
Tracks: 10
Crimson Glory
Year: 1986
Tracks: 8
The progressive metal band Crimson Glory formed in Florida in 1982. Vocalist Midnight, guitarists Jeff Drenning and Ben Jackson, bassist Jeff Lords and drummer Dana Burnell had played together for over three geezerhood earlier Roadrunner signed the band and released the Crimson Glory record album in 1986. The record album received good reviews, prompting MCA to pick up the mathematical group for 1988's Transcendence. Burnell and Jackson were dumped shortly afterward the album's sack, and the duo later on resurfaced as the heavy metal lot Parish, releasing Envision on Alfa Records. Crimson Glory then recruited drummer Ravi Jakhorta for 1991's Unknown & Beautiful; afterward the sessions were complete, Midnight left wing the mathematical group, which briefly forged on with new singer David Van Landing before breakage up. Van Landing, Drenning, Lords and Jakhorta eventually reformed as Erotic Liquid Culture; when Van Landing exited, the odd triple recruited isaac Merrit Singer Wade Black and guitar player Billy Martinez to reunite under the Crimson Glory auspices, issue Astronomica in 1999.
Album Chart: Big debut for Usher's 'Here I Stand'
Wednesday, 18 June 2008
Blood Stain Child
Artist: Blood Stain Child
Genre(s):
Rock
Metal
Folk
Discography:
Mozaiq
Year: 2007
Tracks: 12
Idolator
Year: 2005
Tracks: 12
Mystic Your Heart
Year: 2003
Tracks: 10
Silence of Northern Hell
Year: 2002
Tracks: 7
Naomi Wigs Out!
Supermess Naomi Campbell is losing something besides her mind -- her hair!
After years of working runways, nerves and lace front weaves, the 38-year-old anger management diva appears to be going bald. Never mind a cell phone, somebody throw some Rogaine at her!
See Also
After years of working runways, nerves and lace front weaves, the 38-year-old anger management diva appears to be going bald. Never mind a cell phone, somebody throw some Rogaine at her!
See Also
Devolved
Artist: Devolved
Genre(s):
Metal
Metal: Death,Black
Discography:
Calculated
Year: 2004
Tracks: 12
Technologies
Year: 2001
Tracks: 10
Comprised of vocaliser Nik Carpenter, guitarists Brett Noordin and Mark Walpole, bassist Joel Graham, and drummer John Sankey, Devolved is an Australian expiry metallic element band whose sole album, 2002's Technologies, displays a sophisticated, yet savage, onward motion of the genre.
Greg Packer and NSL
Artist: Greg Packer and NSL
Genre(s):
Drum & Bass
Discography:
Gain (GAIN017)
Year: 2004
Tracks: 2
Movies guide
Friends - The Things They Say 8463
"My favourite line is to go up to a girl who's wearing a pretty dress and say, 'You know, I had to come talk to you because I have the same outfit.' If she laughs, there's potential. If she doesn't, I go home - and put on a pretty dress!" Former FRIENDS star MATTHEW PERRY reveals his favourite chat up line.
See Also
Jolie, Aniston have competing movies coming out on the same day
LOS ANGELES - Brad Pitt's current romantic partner Angelina Jolie and ex-wife Jennifer Aniston will go head-to-head at theatres Oct. 24, when both have a movie coming out.
Jolie stars in Clint Eastwood's missing-child drama "Changeling" while Aniston is part of the ensemble cast in the romantic comedy "He's Just Not That Into You."
Aniston probably will win the dollar battle because her film debuts in nationwide release, while "Changeling" starts in just a few cities to build critical buzz before going wide Oct. 31.
But Jolie, an Academy Award winner for "Girl, Interrupted," likely will lead the acclaim game. Well received by critics in its premiere at the Cannes Film Festival in May, "Changeling" has put Jolie in the running for a best-actress Oscar.
Set in the 1920s and '30s, "Changeling" is based on the true story of a single mom in a nightmare battle with corrupt Los Angeles police trying to cover their mistakes in the investigation surrounding her missing nine-year-old son.
The commercial prospects for "He's Just Not That Into You" are bolstered by an all-star cast including Ben Affleck, Scarlett Johansson, Drew Barrymore and Jennifer Connelly. Directed by Ken Kwapis ("The Sisterhood of the Traveling Pants"), the movie focuses on the mixed signals men and women send in relationships.
Pitt and Jolie - expecting twins, their fifth and sixth children - hooked up after co-starring in the 2005 hit "Mr. and Mrs. Smith" as his marriage to Aniston was unravelling.
Universal Pictures is releasing "Changeling" and Warner Bros. is distributing "He's Just Not That Into You."
See Also
Subscribe to:
Posts (Atom)